| Original language | English (US) |
|---|---|
| Pages (from-to) | 3416-3417 |
| Number of pages | 2 |
| Journal | Cancer |
| Volume | 128 |
| Issue number | 18 |
| DOIs | |
| State | Published - Sep 15 2022 |
Bibliographical note
Funding Information:The NCDB was designed to monitor patterns of cancer care at the local hospital level, and the SEER database reports BCSS. Moreover, the NCDB reports only 5 years of OS. As Weiser et al. mentioned in their limitation sections, the NCDB does not include cancer‐specific death information, and this makes the analysis of cancer‐specific survival impossible. SEER is supported by the Surveillance Research Program in the National Cancer Institute's Division of Cancer Control and Population Sciences. Each regional SEER registry requires every hospital in its geographic area to report all cancer diagnoses. As a result, SEER is able to provide population‐based cohorts to better measure cancer incidence. In contrast, the NCDB is a convenience sample of hospitals accredited by the Commission on Cancer. Although the NCDB does include a Charlson/Deyo Comorbidity Index variable, the lack of BCSS is a limitation of the data set. These important differences between these data sets and their limitations cannot be overemphasized and should be underscored by future research exploring the benefits of chemotherapy for ILC. 1 3 4 5
PubMed: MeSH publication types
- Letter
- Comment
